Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome.
Brown, Audrey E, Jones, David E, Walker, Mark et al. · PloS one · 2015 · DOI
Quick Summary
Researchers grew muscle cells from ME/CFS patients and healthy people in the lab and stimulated them electrically to mimic exercise. They found that muscle cells from ME/CFS patients didn't respond normally to this simulated exercise: they failed to activate a key energy-sensing protein (AMPK) and didn't increase glucose uptake like healthy cells did. This suggests the problem may be rooted in how the muscle cells themselves are built or programmed, not just from being inactive.
Why It Matters
This study provides laboratory evidence that ME/CFS involves genuine muscle cell dysfunction at the molecular level, not just deconditioning. By identifying specific energy-metabolism abnormalities (AMPK signaling and glucose utilization) in cultured patient cells, it opens pathways to develop targeted therapies and strengthens the biological basis for the disease.
Observed Findings
CFS muscle cells showed impaired AMPK phosphorylation in response to 16-hour electrical stimulation, unlike control cells which showed significant activation.
CFS muscle cells did not increase glucose uptake after electrical stimulation, whereas control cells showed significant glucose uptake increases.
Glucose uptake remained responsive to insulin in CFS cells, indicating the exercise-response defect is selective.
CFS muscle cells demonstrated reduced IL-6 secretion both at baseline during differentiation and in response to electrical stimulation.
CFS muscle cells showed elevated myogenin expression in the basal state compared to controls.
Inferred Conclusions
The muscle cell dysfunction in CFS appears to stem from genetic or epigenetic mechanisms intrinsic to the cells, rather than external systemic factors, since abnormalities persist in culture.
The exercise-specific failure of AMPK activation and glucose uptake in CFS cells represents a distinct metabolic defect that may contribute to impaired energy production during activity.
The retention of these cellular differences in cultured conditions provides a viable experimental system for identifying and testing new therapeutic targets.
Remaining Questions
Do these in vitro findings correlate with severity of post-exertional malaise or other clinical features in the same patients?
What This Study Does Not Prove
This in vitro study does not prove these cellular abnormalities are the cause of post-exertional malaise in living patients, nor does it establish causation. The small sample size (10 CFS patients) and heterogeneity of CFS mean findings may not apply to all patients, and cultured cells do not fully replicate the complex physiology of intact muscle in the body.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Are the impairments in AMPK activation and glucose uptake present in all ME/CFS patients or only a subset, and do they vary by disease duration or severity?
Which specific genetic or epigenetic alterations account for the observed differences in muscle cell function?
Can candidate therapeutic interventions designed to restore AMPK activation or glucose uptake reverse these cellular abnormalities in CFS patient-derived cells?